Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Toxicity of Subcutaneous Ketamine in the Management of Cancer Pain | Zendy

Janet Hardy | Zendy; Stephen Quinn | Zendy; Belinda Fazekas | Zendy; John Plummer | Zendy; Simon Eckermann | Zendy; Meera Agar | Zendy; Odette Spruyt | Zendy; Debra Rowett | Zendy; David C. Currow | Zendy

Open Access

Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Toxicity of Subcutaneous Ketamine in the Management of Cancer Pain

Author(s) -

Janet Hardy,

Stephen Quinn,

Belinda Fazekas,

John Plummer,

Simon Eckermann,

Meera Agar,

Odette Spruyt,

Debra Rowett,

David C. Currow

Publication year - 2012

Publication title -

journal of clinical oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 10.482

H-Index - 548

eISSN - 1527-7755

pISSN - 0732-183X

DOI - 10.1200/jco.2012.42.1081

Subject(s) - medicine , ketamine , placebo , adverse effect , cancer pain , randomized controlled trial , anesthesia , odds ratio , incidence (geometry) , cancer , physics , alternative medicine , pathology , optics

The anesthetic ketamine is widely used for pain related to cancer, but the evidence to support its use in this setting is weak. This study aimed to determine whether ketamine is more effective than placebo when used in conjunction with opioids and standard adjuvant therapy in the management of chronic uncontrolled cancer pain. Ketamine would be considered of net benefit if it provided clinically relevant improvement in pain with limited breakthrough analgesia and acceptable toxicity.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research